ZA914559B - Reversible gelation compositions and methods of use - Google Patents

Reversible gelation compositions and methods of use

Info

Publication number
ZA914559B
ZA914559B ZA914559A ZA914559A ZA914559B ZA 914559 B ZA914559 B ZA 914559B ZA 914559 A ZA914559 A ZA 914559A ZA 914559 A ZA914559 A ZA 914559A ZA 914559 B ZA914559 B ZA 914559B
Authority
ZA
South Africa
Prior art keywords
compositions
reversibly gelling
modified
incorporate
oil
Prior art date
Application number
ZA914559A
Other languages
English (en)
Inventor
Abhay Joshi
Joshi Abhay
Shulin Ding
Ding Shulin
Kenneth James Himmelstein
James Himmelstein Kenneth
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24149593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA914559(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ZA914559B publication Critical patent/ZA914559B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA914559A 1990-06-15 1991-06-14 Reversible gelation compositions and methods of use ZA914559B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/539,061 US5252318A (en) 1990-06-15 1990-06-15 Reversible gelation compositions and methods of use

Publications (1)

Publication Number Publication Date
ZA914559B true ZA914559B (en) 1992-03-25

Family

ID=24149593

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA914559A ZA914559B (en) 1990-06-15 1991-06-14 Reversible gelation compositions and methods of use

Country Status (13)

Country Link
US (2) US5252318A (es)
EP (1) EP0533836B1 (es)
JP (1) JP3181912B2 (es)
AT (1) ATE134508T1 (es)
AU (1) AU8201391A (es)
DE (1) DE69117509T2 (es)
ES (1) ES2083581T3 (es)
IE (1) IE74246B1 (es)
IL (1) IL98320A (es)
NZ (1) NZ238430A (es)
PT (1) PT97977B (es)
WO (1) WO1991019481A1 (es)
ZA (1) ZA914559B (es)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
SE512871C2 (sv) * 1992-08-20 2000-05-29 Santen Oy Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension
DK0661045T3 (da) 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
US5624962A (en) * 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation
WO1995000143A1 (en) * 1993-06-24 1995-01-05 Leiras Oy Composition for ophthalmic use
AU7668894A (en) * 1993-08-13 1995-03-14 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
CA2184814A1 (en) 1994-03-04 1995-09-14 Allan S. Hoffman Block and graft copolymers and methods relating thereto
SE9401109D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US5840338A (en) * 1994-07-18 1998-11-24 Roos; Eric J. Loading of biologically active solutes into polymer gels
US5603955A (en) * 1994-07-18 1997-02-18 University Of Cincinnati Enhanced loading of solutes into polymer gels
GB9415290D0 (en) 1994-07-28 1994-09-21 Zeneca Ltd Gel formation
US5599534A (en) * 1994-08-09 1997-02-04 University Of Nebraska Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use
DK0725628T3 (da) * 1994-08-30 2001-12-27 Alcon Lab Inc Termisk geldannende lægemiddelindgivelsesvehikler indeholdende celluloseethere
US5827835A (en) * 1994-08-30 1998-10-27 Alcon Laboratories, Inc. Thermally-gelling emulsions
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5985383A (en) * 1995-03-15 1999-11-16 Acushnet Company Conforming shoe construction and gel compositions therefor
US5939485A (en) * 1995-06-19 1999-08-17 Medlogic Global Corporation Responsive polymer networks and methods of their use
US5955159A (en) * 1995-03-15 1999-09-21 Acushnet Company Conforming shoe construction using gels and method of making the same
US5939157A (en) * 1995-10-30 1999-08-17 Acushnet Company Conforming shoe construction using gels and method of making the same
DE19511322C2 (de) * 1995-03-28 1999-09-02 Mann Gerhard Chem Pharm Fab Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung
WO1997000275A2 (en) * 1995-06-16 1997-01-03 Gel Sciences, Inc. Responsive polymer networks and methods of their use
JP3766707B2 (ja) * 1995-10-25 2006-04-19 ディップソール株式会社 亜鉛及び亜鉛合金の撥水処理用水溶性組成物及び撥水処理方法
US5766704A (en) * 1995-10-27 1998-06-16 Acushnet Company Conforming shoe construction and gel compositions therefor
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5866120A (en) * 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5723131A (en) * 1995-12-28 1998-03-03 Johnson & Johnson Vision Products, Inc. Contact lens containing a leachable absorbed material
US6280745B1 (en) 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
WO1998006438A2 (en) * 1996-08-12 1998-02-19 Medlogic Global Corporation Composition for pharmaceutical applications
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
AU5906898A (en) * 1997-01-02 1998-07-31 Medlogic Global Corporation Responsive polymer networks and methods of their use
AU6134298A (en) * 1997-01-24 1998-08-18 Medlogic Global Corporation Conformable structures
WO1998055147A2 (en) * 1997-06-06 1998-12-10 Battelle Memorial Institute Reversible geling co-polymer and method of making
GB9718568D0 (en) 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
US20040063678A1 (en) * 1997-10-06 2004-04-01 Bausch & Lomb Incorporated Dexamethasone Gel
DE19744113A1 (de) * 1997-10-06 1999-04-15 Mann Gerhard Chem Pharm Fab Dexamethason-Gel
US6417247B1 (en) * 1997-10-14 2002-07-09 Beth L. Armstrong Polymer/ceramic composites
CA2316248A1 (en) * 1997-12-23 1999-07-01 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
US20040228794A1 (en) * 1998-04-10 2004-11-18 Battelle Memorial Institute Therapeutic agent carrier compositions
US6159483A (en) * 1998-06-01 2000-12-12 Colgate-Palmolive Company Stabilized liquid aqueous composition
US5968480A (en) * 1998-07-09 1999-10-19 Colgate Palmolive Company Oral composition exhibiting enhanced antiplaque efficacy
US6337130B1 (en) 1998-07-30 2002-01-08 Zeneca Limited Acid-triggered release microcapsules
US6316011B1 (en) 1998-08-04 2001-11-13 Madash, Llc End modified thermal responsive hydrogels
CA2345414A1 (en) * 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Eyedrops for promoting lacrimal secretion or treating keratoconjunctival disorders containing natriuretic peptide as active ingredient
US6312666B1 (en) 1998-11-12 2001-11-06 3M Innovative Properties Company Methods of whitening teeth
US6669927B2 (en) 1998-11-12 2003-12-30 3M Innovative Properties Company Dental compositions
US6312667B1 (en) 1998-11-12 2001-11-06 3M Innovative Properties Company Methods of etching hard tissue in the oral environment
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
IL146801A0 (en) * 1999-06-11 2002-07-25 Pro Duct Health Inc Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US20040037891A1 (en) * 1999-10-04 2004-02-26 Karagoezian Hampar L. Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide
US20040234457A1 (en) * 1999-10-19 2004-11-25 The Procter & Gamble Company Methods of preventing and treating SARS using low pH respiratory tract compositions
US20040033260A1 (en) * 1999-10-19 2004-02-19 The Procter & Gamble Company Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
WO2001041735A2 (en) * 1999-12-07 2001-06-14 Amgen Inc. Thermosensitive biodegradable hydrogels based on low molecular weight pluronics
FR2802097B1 (fr) * 1999-12-14 2002-12-13 Invest S Therapeutiques Essais Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
US6660247B1 (en) * 2000-06-23 2003-12-09 Battelle Memorial Institute Multiple stimulus reversible hydrogels
US6303290B1 (en) 2000-09-13 2001-10-16 The Trustees Of The University Of Pennsylvania Encapsulation of biomaterials in porous glass-like matrices prepared via an aqueous colloidal sol-gel process
US7803392B2 (en) * 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
CN1204922C (zh) * 2001-02-15 2005-06-08 株式会社三和化学研究所 新的眼科用组合物
US6995209B2 (en) * 2001-03-21 2006-02-07 Madash Llc Thermally reversible water in oil in water emulsions
JP2003089752A (ja) * 2001-03-23 2003-03-28 Canon Inc 刺激応答性ポリマーを含む組成物、それを含むインク組成物、並びに該インク組成物を用いた画像形成方法および装置
FR2823439A1 (fr) * 2001-04-13 2002-10-18 Oreal Composition de bain gelifiantes, relaxantes
DE10132876A1 (de) * 2001-07-06 2003-01-30 Medproject Pharma Entwicklungs Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge
US20080063620A1 (en) * 2001-08-13 2008-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel reverse thermo-sensitive block copolymers
US20030082235A1 (en) * 2001-08-13 2003-05-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel reverse thermo-sensitive block copolymers
US6620405B2 (en) 2001-11-01 2003-09-16 3M Innovative Properties Company Delivery of hydrogel compositions as a fine mist
DE60239556D1 (de) 2001-11-14 2011-05-05 Durect Corp Katheterinjizierbare depotzusammensetzungen und deren verwendung
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US20030170289A1 (en) * 2001-11-14 2003-09-11 Guohua Chen Injectable depot compositions and uses thereof
US7204997B2 (en) * 2002-01-29 2007-04-17 Supratek Pharma Inc. Responsive microgel and methods related thereto
AU2003225516A1 (en) * 2002-03-26 2003-10-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Responsive biomedical composites
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
EP1878447A3 (en) * 2002-05-09 2008-12-31 Ultrast LLC Medium for contrast enhancement or convenience for ultrasonic, endoscopic and other medical examinations
JP2005524711A (ja) * 2002-05-09 2005-08-18 ウルトラスト・リミテッド・ライアビリティ・カンパニー コントラストの強調のための、または超音波、内視鏡および他の医療検査に有用な媒質
DE10224352A1 (de) * 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
JP3891571B2 (ja) * 2002-06-14 2007-03-14 キヤノン株式会社 機能性組成物、それを用いた画像形成方法及び画像形成装置
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
MXPA05001244A (es) 2002-07-31 2005-06-08 Alza Corp Composiciones de deposito de polimero multimodal inyectable y usos de las mismas.
AU2002359397B2 (en) 2002-07-31 2009-01-29 Durect Corporation Injectable depot compositions and uses thereof
CN100453066C (zh) 2002-12-04 2009-01-21 参天制药株式会社 利用结膜下储存库的药物释放系统
US7223826B2 (en) * 2003-01-30 2007-05-29 3M Innovative Properties Company Amide-functional polymers, compositions, and methods
US20040185013A1 (en) * 2003-01-30 2004-09-23 Burgio Paul A. Dental whitening compositions and methods
US20040151691A1 (en) * 2003-01-30 2004-08-05 Oxman Joel D. Hardenable thermally responsive compositions
IL155866A0 (en) * 2003-05-12 2003-12-23 Yissum Res Dev Co Responsive polymeric system
TWI336257B (en) 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
CA2839847C (en) 2003-06-13 2016-03-15 Masood A. Chowhan Ophthalmic compositions containing a synergistic combination of two polymers
US7914803B2 (en) 2003-06-13 2011-03-29 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of three polymers
US20050002996A1 (en) * 2003-07-02 2005-01-06 Milan Sojka Sustained release compositions and controlled delivery method
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
DE10350248A1 (de) * 2003-10-28 2005-06-16 Magnamedics Gmbh Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik
GB2408937A (en) * 2003-12-09 2005-06-15 Johnson & Johnson Medical Ltd pH dependent medicinal compositions
GB0329507D0 (en) * 2003-12-19 2004-01-28 Guillon Michel Contect lens
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8246949B2 (en) * 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060147485A1 (en) * 2005-01-04 2006-07-06 Morten Pedersen Oil-in-water formulation of avermectins
DE102005035879A1 (de) * 2005-07-30 2007-02-01 Paul Hartmann Ag Hydrogel
US20070048338A1 (en) * 2005-08-26 2007-03-01 Ladd Byron S Compositions and methods for surface treatment in medical and surgical procedures
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
US20070248630A1 (en) * 2006-04-20 2007-10-25 Friden Phillip M Pharmaceutical formulations for iontophoretic methotrexate delivery
AU2007240389A1 (en) * 2006-04-20 2007-11-01 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic drug delivery
EP2035015A4 (en) * 2006-05-01 2009-11-11 Riolan Technologies Inc COMPOSITIONS, METHODS AND KITS FOR DRY EYE TREATMENT
EP1873205A1 (en) * 2006-06-12 2008-01-02 Corning Incorporated Thermo-responsive blends and uses thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
EP2158898A1 (en) 2006-06-23 2010-03-03 Aegis Therapeutics LLC Stabilizing alkylglycoside compositions and method thereof
US8334265B2 (en) 2006-08-31 2012-12-18 Clinuvel Pharmaceuticals Limited Method of treatment of photodermatoses
WO2008053810A1 (fr) * 2006-10-30 2008-05-08 Mitsui Chemicals, Inc. Gel sensible au ph, procédé de fabrication dudit gel, et soupape sensible au ph
RU2340327C1 (ru) * 2007-05-03 2008-12-10 Лев Давидович Раснецов Офтальмологический гель и способ его приготовления
WO2008137872A1 (en) * 2007-05-04 2008-11-13 Personics Holdings Inc. Earguard sealing system i: multi-chamber systems
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
US8718313B2 (en) * 2007-11-09 2014-05-06 Personics Holdings, LLC. Electroactive polymer systems
DE102007059939A1 (de) 2007-12-12 2009-06-18 Müller-Schulte, Detlef, Dr. Auflösbare, magnetische und unmagnetische Polymerträger zur Abtrennung und Wiedergewinnung von Zellen und Biosubstanzen
US8142870B2 (en) * 2007-12-13 2012-03-27 Personics Holdings Inc. Energy responsive conformal device
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
ES2550160T3 (es) 2008-03-27 2015-11-04 Clinuvel Pharmaceuticals Limited Terapia para el vitíligo
AU2009228093B2 (en) 2008-03-28 2014-08-07 Neurelis, Inc. Administration of benzodiazepine compositions
KR101101321B1 (ko) * 2008-11-03 2012-01-02 주식회사 엠씨티티 상처 치유를 위한 하이드로 겔 형태의 세포전달용 비히클 및 그 제조방법
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
WO2010144194A1 (en) 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
IT1397132B1 (it) * 2009-12-01 2013-01-04 Alfa Wassermann Spa Composizioni comprendenti antiinfiammatori non steroidei.
EP2534106B1 (en) 2010-02-10 2019-10-16 Queen's University At Kingston Method for modulating ionic strength
PT2544532T (pt) 2010-03-12 2017-06-02 Monsanto Technology Llc Composições de gel agroquímicas
WO2012009706A1 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Drop generating device
KR20150031340A (ko) 2010-07-15 2015-03-23 코린시언 아프샐믹 인코포레이티드 안과용 약물 전달
JP2013531548A (ja) 2010-07-15 2013-08-08 コリンシアン オフサルミック，インコーポレイティド 遠隔治療及び遠隔モニタリングを実施する方法及びシステム
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
AU2011342287B2 (en) * 2010-12-15 2015-09-17 Greencentre Canada Systems and methods for use of water with switchable ionic strength
GB201100820D0 (en) 2011-01-18 2011-03-02 Guillon Michel Lenses
EP2487185A1 (en) 2011-02-11 2012-08-15 Clinuvel Pharmaceuticals Limited Hexapeptide with improved activity in the repair of cellular DNA of dermal cells
RU2013142684A (ru) 2011-02-22 2015-03-27 Реджентс Оф Юниверсити Оф Миннесота (Сша) Инкапсулированные в диоксиде кремния биоматериалы
DK2689774T3 (en) 2011-03-21 2019-04-01 Broda Tech Co Ltd REVERSE TERMOREVERSIBLE HYDROGEL COMPOSITIONS
US20160144038A1 (en) 2014-11-20 2016-05-26 Broda International, LLC Water-soluble supramolecular complexes
EP2699229A2 (en) * 2011-04-22 2014-02-26 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
JP6148228B2 (ja) 2011-05-18 2017-06-14 ユーメデリス ファーマシューティカルズ，インク． 改善されたペプチド製剤
PL3415139T3 (pl) 2011-06-14 2022-07-11 Neurelis, Inc. Podawanie benzodiazepiny
AU2012312816A1 (en) 2011-09-22 2014-04-24 Bausch & Lomb Incorporated Ophthalmic gel compositions
US20130101547A1 (en) 2011-10-19 2013-04-25 Allergan, Inc. Thermoresponsive compositions for dermatological use and methods thereof
US20130150812A1 (en) 2011-12-12 2013-06-13 Corinthian Ophthalmic, Inc. High modulus polymeric ejector mechanism, ejector device, and methods of use
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
US20160051503A1 (en) 2012-08-31 2016-02-25 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
JP6525456B2 (ja) 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
EP3444281B1 (en) 2012-11-20 2021-11-03 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
US9534236B2 (en) 2013-03-08 2017-01-03 Regents Of The University Of Minnesota Membranes for wastewater-generated energy and gas
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
KR20230084337A (ko) 2014-05-28 2023-06-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
US10035719B2 (en) 2014-10-15 2018-07-31 Regents Of The University Of Minnesota System and membrane for wastewater-generated energy and gas
PT3721868T (pt) 2015-01-26 2022-08-12 Bausch & Lomb Composição para suspensão oftálmica
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
CA3002384C (en) 2015-10-25 2021-02-16 Iview Therapeutics, Inc. Pharmaceutical formulations that form gel in situ
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3634550A4 (en) 2017-06-10 2021-03-03 Eyenovia, Inc. METHODS AND DEVICES FOR HANDLING A FLUID AND DELIVERING THE FLUID TO THE EYE
IL311775A (en) 2018-01-03 2024-05-01 Mederis Diabetes Llc Improved peptide drugs for the treatment of NASH and other disorders
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
EP3886829A4 (en) * 2018-11-26 2021-12-22 AiViva Biopharma, Inc. PHARMACEUTICAL BIOSOLUBLE GELS FOR DRUG ADMINISTRATION
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB223166A (en) * 1923-07-11 1924-10-13 Albert Edward Young Improvements in or relating to the sealing of chambers used in the treatment of material in sheet form by air or gas
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
CA1141663A (en) * 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
ATE6466T1 (de) * 1979-10-26 1984-03-15 Smith And Nephew Associated Companies P.L.C. Autoklavierbare emulsionen.
US4406884A (en) * 1981-06-23 1983-09-27 The Procter & Gamble Company Topical antimicrobial composition
EP0075540B1 (en) * 1981-09-23 1986-10-22 Ciba-Geigy Ag A coated absorbant substrate or shaped article, containing a water-soluble and/or volatile active agent
JPS59122422A (ja) * 1982-12-29 1984-07-14 Toko Yakuhin Kogyo Kk 口腔用消炎鎮痛ゲル剤
US4474753A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
CA1224148A (en) * 1983-05-16 1987-07-14 John L. Haslam Drug delivery system utilizing thermosetting gels
EP0501523B1 (en) * 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
DE3440352A1 (de) * 1984-11-05 1986-05-07 Dr. Thilo & Co GmbH, 8029 Sauerlach Dry-eye-packung
JPS6267017A (ja) * 1985-09-19 1987-03-26 Sanwa Kagaku Kenkyusho:Kk 被膜形成型揮散性薬物含有軟膏剤
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4692454A (en) * 1986-02-03 1987-09-08 Warner-Lambert Company Opthalmic use of quinolone antibiotics
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
DE3721574A1 (de) * 1987-06-30 1989-01-12 Kettelhack Riker Pharma Gmbh Arzneimittel in form von pellets mit enzymatisch kontrollierter arzneistoff-freisetzung
FR2618333B1 (fr) * 1987-07-20 1990-07-13 Merck Sharp & Dohme Composition pharmaceutique et/ou cosmetique a usage topique contenant de la gomme rhamsam
US4917892A (en) * 1988-06-28 1990-04-17 Temple University Encapsulated topical delivery system
JP2670812B2 (ja) * 1988-07-08 1997-10-29 株式会社コーセー 液状化粧料
GB2223166B (en) * 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use

Also Published As

Publication number Publication date
IL98320A (en) 1995-10-31
EP0533836B1 (en) 1996-02-28
US5252318A (en) 1993-10-12
US5441732A (en) 1995-08-15
ATE134508T1 (de) 1996-03-15
IL98320A0 (en) 1992-06-21
IE74246B1 (en) 1997-07-16
IE912033A1 (en) 1991-12-18
ES2083581T3 (es) 1996-04-16
EP0533836A4 (en) 1993-04-21
DE69117509D1 (de) 1996-04-04
WO1991019481A1 (en) 1991-12-26
PT97977B (pt) 1998-11-30
AU8201391A (en) 1992-01-07
DE69117509T2 (de) 1996-09-19
NZ238430A (en) 1993-03-26
JP3181912B2 (ja) 2001-07-03
EP0533836A1 (en) 1993-03-31
JPH05508154A (ja) 1993-11-18
PT97977A (pt) 1992-03-31

Similar Documents

Publication Publication Date Title
EP0533836A4 (en) Reversible gelation compositions and methods of use
EP0725628B1 (en) Thermally-gelling drug delivery vehicles containing cellulose ethers
WO2009028764A1 (en) Thermo-reversible coacervate combination gels for protein delivery
KR101666792B1 (ko) 핵산 및 키토산을 포함하는 온도감응성 하이드로겔 조성물
EP0528461A2 (en) Delayed borate crosslinked fracturing fluid
CA2251281C (en) Drug composition with controlled drug release rate
ATE536869T1 (de) Auf glucan-film basierte wirkstoffverabreichungssysteme
CA2116563A1 (en) Dry gel pharmaceutical composition
ES2117825T3 (es) Geles formados por la interaccion de polivinilpirrolidona con derivados de quitosano.
DE3684121D1 (de) Pharmazeutische zusammensetzung vom fluessig/gel-phasenuebergangstyp.
ATE349202T1 (de) Formulierung auf heparin-, glycosaminoglykan- oder heparinoidbasis und verwendung der formulierung sowie der formulierungsgrundlage
BR0116186A (pt) Sistema de gelificação reversìvel para liberação de droga ocular
EP0386960A3 (en) Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
JP2001521887A (ja) Ｎｓａｉ薬送達用局所組成物
ES2066896T3 (es) Forma oral de farmaco de lipidos.
BR9811574B1 (pt) composição farmacêutica oftálmica estéril.
EP0735861A1 (en) Tissue moisturizing and antimicrobial compositions
DK0670713T3 (da) Farmaceutisk formulering
WO2002092055A1 (en) Oxidized collagen formulations for use with non-compatible pharmaceutical agents
CN1571678A (zh) 含有丙二醇作为唯一助溶剂的即用型扑热息痛注射溶液
US5827835A (en) Thermally-gelling emulsions
EA200200914A1 (ru) Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
Sailaja et al. An overall review on topical preparation-gel
ATE199302T1 (de) Zusammensetzung zur viskositätskontrolle von flüssigen nährmitteln
CN115634234B (zh) 一种含氯己定/枙子苷/透明质酸的泊洛沙姆407抑菌抗炎温敏水凝胶及制备与应用